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Abstract
Background
Late presentation for human immunodeficiency virus (HIV) care is a major impediment for
the success of antiretroviral therapy (ART) outcomes. The role that stigma plays as a poten-
tial barrier to timely diagnosis and treatment of HIV among people living with HIV/AIDS
(acquired immunodeficiency syndrome) is ambivalent. This review aimed to assess the best
available evidence regarding the association between perceived HIV related stigma and
time to present for HIV/AIDS care.
Methods
Quantitative studies conducted in English language between 2002 and 2016 that evaluated
the association between HIV related stigma and late presentation for HIV care were sought
across four major databases. This review considered studies that included the following out-
come: ‘late HIV testing’, ‘late HIV diagnosis’ and ‘late presentation for HIV care after testing’.
Data were extracted using a standardized Joanna Briggs Institute (JBI) data extraction tool.
Meta- analysis was undertaken using Revman-5 software. I2 and chi-square test were used
to assess heterogeneity. Summary statistics were expressed as pooled odds ratio with 95%
confidence intervals and corresponding p-value.
Results
Ten studies from low- and middle- income countries met the search criteria, including six (6)
and four (4) case control studies and cross-sectional studies respectively. The total sample
size in the included studies was 3,788 participants. Half (5) of the studies reported a signifi-
cant association between stigma and late presentation for HIV care. The meta-analytical
association showed that people who perceived high HIV related stigma had two times more
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probability of late presentation for HIV care than who perceived low stigma (pooled odds
ratio = 2.4; 95%CI: 1.6–3.6, I2 = 79%).
Conclusions
High perceptions of HIV related stigma influenced timely presentation for HIV care. In order
to avoid late HIV care presentation due the fear of stigma among patients, health profession-
als should play a key role in informing and counselling patients on the benefits of early HIV
testing or early entry to HIV care. Additionally, linking the systems and positive case tracing
after HIV testing should be strengthened.
Background
Globally, 38.8 million people were living with human immunodeficiency virus (HIV) at the
end of 2015[1], and the burden of the epidemic varies considerably between countries and
regions. Sub-Saharan Africa (SSA) contributed 76% (29 million) of the total HIV-infected peo-
ple, 76% (1.9 million) of the total new HIV infections, and 75% (0.9 million) of the total HIV/
AIDS deaths[1]
The success of ART program of a country depends on the series of steps HIV-infected per-
son takes from initial HIV diagnosis through their consistent ART treatment, a cascade called
HIV care continuum [2, 3]. This included HIV testing and diagnosis, assessment for ART eli-
gibility, patient retention, and immunologic success and virological suppression via treatment
adherence. Even though a number of initiatives have been devoted to curb the consequences
of negative HIV outcomes, there are several challenges in every series of HIV care continuum.
Late presentation for HIV care (hereon in referred to as LP) is one of the several challenges in
the continuum[3]. The definition of LP is disparate, and a number of definitions have been
used to date: i) when the diagnosis of an AIDS defining condition occurs either before or con-
comitantly to an HIV diagnosis [4]; ii) when the diagnosis of an AIDS defining condition
occurs during the subsequent six months to an HIV diagnosis,[5, 6]; iii) when the diagnosis of
an AIDS defining condition occurs during the following year of an HIV diagnosis [7]; iv)
when the baseline CD4 count is <200 [8] or <350 [9, 10] cells/μl, and v) when baseline CD4
cell count is <200 cells/μl and/or with an AIDS defining disease [11].
A number of HIV infected patients in developing [12–16] and developed [17, 18] countries
are often diagnosed late. For example, studies from Uganda[16], Gabon[15] and India[13]
reported that the prevalence rate of late presentation for HIV care was 40, 45 and 46% respec-
tively. In Europe, the prevalence of LP has been reported to be roughly between 15–66%[17,
18]. The major factors affecting late presentation for HIV care included age, sex, educational
status, not having a permanent house, having two and more lifetime sexual partners, having
contact with female sex workers (FSW), poor social support, fear of stigma, fear of losing job,
fear of drug side effects, intravenous drug use, and reported severe illness[12–14, 19–23].
LP has numerous consequences including: (i) increased risk of progression of the infection
and transmission with severe public health implications [24]; ii) increased risk of anti-retrovi-
ral therapy (ART) drug resistance [24]; (iii) acceleration of immunological and clinical failure
[23, 25, 26]; and vi) increased risk of poor prognosis including early mortality[4, 23, 25, 26].
Henceforth, lessening the time gap that elapses between HIV infection and the commence-
ment of ART is important to halt progression of the infection and to hasten immunological
recovery. Perceived HIV related stigma (hereon in referred to as stigma) plays a major
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contribution among the multiple factors that contribute to HIV infected patients presenting
late for HIV/AIDS care [20, 27, 28].
Stigma is a prejudice, negative attitudes and abuse directed at people living with HIV and
AIDS. It is process of devaluation that heads to shame and significantly discredits an individual
in the eyes of others [29, 30]. Stigma has also been related to how much people living with HIV
(PLHIV) perceive that the community stigmatizes someone with HIV[31]. Studies across the
world indicate that stigma is multifaceted, tending to build upon and reinforcing negative
implications through the association of HIV/AIDS with already marginalized behaviours, such
as sex work, substance use and homosexual and transgender sexual practice [32–35]. A study
from Botswana suggested that stigma was a primary barrier for HIV testing [27]. According to
this study, prevalence of delayed testing for HIV was 40% and 51% of them reported fear of a
positive result, which was often due to stigma.
Another study from Venezuela also depicted that fear of stigma was the main barrier for
HIV testing [36]. Similarly, a case control study conducted in Ethiopia revealed that PLHIV
who perceived stigma were three times more likely to present late to HIV/AIDS care than their
counterparts[23]. On the contrary, another case control study conducted in southwest Ethio-
pia reported that stigma was not related with LP [14]. However, the measurement of perceived
stigma varies within the literature. For example, one study conducted in Ethiopia used a 23
items and four point Likert scale [37] whereas another from the same country used a nine
items scale[23]. Given that there is ambiguity surrounding the relationship between perceived
stigma and LP, assessing the role of stigma as a barrier to LP is necessary.
To our knowledge, there is no published systematic review and meta-analysis so far on this
topic. In addition, our preliminary search of databases found no current or ongoing systematic
reviews on this or a similar topic. Furthermore, the lack of high quality data on the correlation
between stigma and LP is a challenge; preventing HIV/AIDS control programs from providing
reliable evidence to inform tailored intervention strategies. The current study investigated the
association between stigma and LP among PLHIV adults.
Methods and participants
Study protocol
This review was conducted according to an a priori published protocol[38].
Study design
A systematic review and meta-analysis was performed on studies conducted in English lan-
guage between 2002 and 2016. The objective of the current review was to identify the best
available evidence regarding the association between stigma and late presentation for HIV
care.
Types of participants
The review considered studies reporting on HIV-positive participants aged 15 years and older
who had visited ART clinic for the first time in their respective health institution/s. HIV
infected patients who received prior HIV/AIDS care in another health institution/s were
excluded from this review.
Types of exposure
The review considered studies that evaluated stigma. Stigma was measured using a validated
tool, either by self-administered questionnaire or interviewing method for PLHIV, health
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workers, or the general population. HIV-related stigma was dichotomized in to high or low.
High stigma was defined if the study participants mentioned that they had experienced stigma
or scored a mean above the overall mean of the items that were used to assess stigma and
discrimination.
Types of outcomes
The review considered studies that included the following outcomes:
Time at presentation for HIV care, measured by immune status or stage of HIV infection;
LP was defined as WHO stage 3 or 4, or CD4<200 cells/μL, or patients classified at diagnosis
with HIV disease-stage B or C according to the 1993 CDC classification. However, in recent
years (2014 and after), LP was also considered < 350 cells/μL as countries revised their eligibil-
ity criteria for ART treatment.
Search strategy
An initial limited search of MEDLINE and CINAHL was undertaken followed by analysis of
the text words contained in the title and abstract, and of the index terms used to describe arti-
cle. A second search using all identified keywords and index terms was undertaken across four
included databases: PubMed, CINAHL, SCOPUS and Web of Science databases; and govern-
ment websites such as AIDS.gov, CDC and WHO, and specific journals such as Health Sci-
ences Library and Informatics Center, Cochrane Reviews, Gray Literature in Health Research,
MedNar and Open Grey. Finally, the reference list of all identified reports and articles was
searched for additional studies. Only studies published in English between 2002 and 2016 were
considered for inclusion in this review. The key words included "HIV diagnosis", "AIDS diag-
nosis", "HIV testing", "HIV presentation", "HIV care", "HIV treatment", “stigma”, and “dis-
crimination”. Full search strategy is provided in S1 Table.
Selection of studies
Only quantitative studies including clinical trials, prospective and retrospective cohort studies,
case control studies, cross- sectional studies, case series and individual case reports were
selected for inclusion. Two authors (HAG and ATG), independently, critically appraised the
papers for methodological validity prior to inclusion in the review using standardized critical
appraisal instruments from the Joanna Briggs Institute Meta Analysis of Statistics Assessment
and Review Instrument (JBI-MAStARI) (S2 Doc). Any disagreements between the reviewers
were resolved through discussion, or with consultation to a third reviewer. Articles that did
not meet all eligibility criteria were excluded and reasons were noted (Fig 1).
Quality appraisal
The methodological quality of the papers was reviewed using JBI-MAStARI critical appraisal
instrument (S1 Doc, S2 Table), which contains 9 questions, and articles receive values repre-
senting the extent to which they meet the following criteria: Yes, No, Unclear and Not ap-
plicable. Any disagreements between the reviewers were resolved through discussion or by
consulting a third reviewer. The risk of bias was also assessed based on Agency for Healthcare
Research and Quality (AHRQ) criteria[39]. Authors of primary studies were contacted to clar-
ify missing or unclear data.
Meta-analysis of stigma and late HIV care presentation
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Data collection
Quantitative data were extracted from papers included in the review using the standardized
data extraction tool from JBI-MAStARI (S2 Doc). The extracted data included specific details
about the exposure, populations, study methods and outcomes of significance to the review
question and specific objectives. Corresponding authors of two studies[40, 41] were communi-
cated via e-mail and asked to fill a prepared two by two contingency table in word consisting
of numbers of PLHIV perceiving high and low HIV related stigma in row, and numbers of
PLHIV presented late and early to HIV care in a column. However, only author of one study
[40] replied the request.
Data analyses
The quantitative data were abstracted into an Excel 2011 and included details of authors, year,
country, study design, population, setting, sample size, outcome and its measurement and key
Fig 1. PRISMA 2009 Flow Diagram. This figure presents the results of the systematic search and reasons of exclusion.
https://doi.org/10.1371/journal.pone.0173928.g001
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findings of the study. The authors assessed clinical heterogeneity of the studies and were
acceptable to combine each outcome to meta-analysis. Standard Chi-square test and I2 were
used to test the statistical heterogeneity among the studies, with significant heterogeneity
detected at the P value < 0.05. Meta-analysis was undertaken for LP and stigma using Rev-
Man-5 Software[42]. Meta-analysis was considered if I2 was below 85%[43]. Mantel Haenszel
statistical method was used to calculate effect sizes, and forest plots to describe for the meta-
analyses of stigma with LP.
Pooled unadjusted odds ratio (OR)[44] estimates and their 95% confidence intervals (CI)
were calculated using random effect meta-analysis[43, 45, 46]. Publication bias was assessed
using funnel plot. Sensitivity test was performed by omitting and entering small studies and
deviant results from the rest of the studies (outliers). PRISMA reporting guidelines for system-
atic reviews has been used to report the review[47] (S1 PRISMA Checklist).
Ethical considerations
Quality scores are reported in S1 Doc and S2 Table. All studies reported ethical statement.
Results
Description of studies
Two thousand four hundred and thirty eight (2438) potential studies including from literature
search (2435) and bibliographic review (3) were identified. Six hundred and eighty seven (687)
duplicated records and 1751 abstracts were excluded after screening (Fig 1). Full texts were
obtained for 74 articles, of which 43 were from low- and middle-income countries (LMICs)
and 34 were from high-income countries (HICs); 3 records (reviews) were conducted in both
LMICs and HICs. Upon further screening, all of the articles (34) from HICs were excluded for
the following reasons: 16 articles did not report on the desired outcome, 13 did not report the
exposure of interest, 4 did not utilize objective measurement of exposure and 1 was qualitative
study design. Thirty three (33) studies from LMICs were also excluded upon further screening
due to the following reasons: 12 articles did not report on the desired outcome, 10 did not
report the exposure of interest, 5 did not utilize objective measurement of exposure, 1 did not
utilize reliable measurement of exposure, 3 were conducted among children and 2 were quali-
tative studies designs. A total of 10 studies were included to assess the association between LP
and stigma.
Table 1 shows the main characteristics and outcomes of reviewed studies[14, 19, 22, 23, 36,
40, 41, 48–50]. Studies from Ethiopia [14, 19, 23, 48, 49] were overrepresented (5), and the oth-
ers were from Mexico[41], Brazil[50], Venezuela[36], Zimbabwe[40] and Kenya[22]. All stud-
ies had relatively high sample size and the total sample size was 3,788. The studies were
analytical and descriptive in type including: six (6) case control studies [14, 19, 23, 40, 48, 49]
and four (4) cross-sectional studies[22, 36, 41, 50].
Methodological quality
Ten studies, 6 case control studies[14, 19, 23, 40, 48, 49] and 4 cross-sectional studies[22, 36,
41, 50], were included in the review. The methodological quality of each study is described
below in detail and their score is presented in S2 Table.
Six case-control studies[14, 19, 23, 40, 48, 49] met seven (7) out of eight (8) criteria of the
JBI critical appraisal. The study sample sizes were representative of all respective adult popula-
tions living with HIV/AIDS. Outcome was measured reliably and assessed using objective cri-
teria. Confounding factors were identified and strategies to deal with them were stated.
Meta-analysis of stigma and late HIV care presentation
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Table 1. Characteristics of included articles (n = 10).
Author Year Country Design Population Setting n Outcome Outcome Measurement Key findings
Abaynew
et al.[23]
2011 Ethiopia Case
control
HIV + adults Public
hospital
320 Late
presentation for
HIV/AIDS care
(LP)
Late presenters were HIV
positive individuals who had
WHO clinical stage 3 or 4
irrespective of CD4
lymphocyte count or a CD4
lymphocyte count of less than
200/uL irrespective of clinical
staging at the time of first
presentation to the ART clinics
of the hospitals.
Stigma was a significant
predictor for LP (AOR = 3.1,
95%CI: 1.1–8.8).
Aniley et al.
[48]
2016 Ethiopia Case
control
HIV + adults Public
hospital
392 Late HIV
diagnosis
(LHD)
Patients who diagnosed late
were people living with HIV
who had CD4 count<350 cells/
mm3 or WHO clinical stage 3
and 4 regardless of the CD4
count at first presentation
Stigma was marginally
associated with late HIV
diagnosis (AOR = 1.7, 95%CI:
1–2.9).
Beyene at
al.[49]
2015 Ethiopia Case
control
HIV + adults Public
hospital
534 LHD Patients who diagnosed late
were people living with HIV
whose baseline CD4 T cell
count was < 200/μl of blood.
Stigma was a significant
predictor of LHD (High vs low
internalized stigma score:
AOR = 16.6,95%CI: 8.3–33.4);
Medium vs low internalized
stigma score: AOR = 4.9, 95%
CI: 3.1–7.8).
Bonjour
et al.[36]
2008 Venezuela Cross-
sectional
HIV + adults Public
hospital
225 Delayed HIV
diagnosis
(DHD)
Late presentation at diagnosis
was defined as patients
classified at diagnosis with
HIV disease-stage B or C
according to the 1993 Centers
for Disease Control and
Prevention (CDC)
classification.
Stigma was not a significant
predictor for DHD (AOR = 1.4,
95%CI: 0.6–3.3).
Carrizosa
et al.[41]
2009 Mexico Cross-
sectional
HIV + adults HIV
clinic
362 Late HIV testing
(LHT)
Late testers were defined as
participants who had at least
one of: (1) an AIDS-defining
illness within 1 year of first
positive HIV test; (2) a date of
AIDS diagnosis within 1 year
of first positive HIV test; or (3)
an initial CD4 cell count below
200cells per microliter within 1
year of first positive HIV test.
Stigma was a significant
correlate for LHT (AOR = 0.7,
95% CI: 0.5–0.9).
Gelaw et al.
[19]
2015 Ethiopia Case
control
HIV + adults Public
hospital
442 LP Patients who diagnosed late
were people living with HIV
who had CD4 count<350 cells/
mm3 or WHO clinical stage 3
and 4 regardless of the CD4
count at first presentation
Stigma was not statistically
associated with LP (AOR = 1.4,
95%CI: 0.9–2.1).
Gesesew
et al.[14]
2013 Ethiopia Case
control
HIV + adults Public
hospital
309 LP Late presenters were HIV
positive individuals who had
WHO clinical stage 3 or 4
irrespective of CD4
lymphocyte count or a CD4
lymphocyte count of less than
200/uL irrespective of clinical
staging at the time of first
presentation to the ART clinics
of the hospitals.
Stigma was not a significant
predictor of LP.
MacCarthy
et al.[50]
2014 Brazil Cross-
sectional
HIV+ men who
have sex with
men (MSM)
Public
hospital
740 LP LP was defined as having a
first CD4 count <350 cells/
mm3
Stigma was not statistically
associated with LP (AOR = 1.2,
95%CI: 0.85–1.77).
(Continued)
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Comparisons were made among groups, and appropriate method of analysis and statistics was
utilized in the study. However, since these studies were case-control, appraisal based on ade-
quate follow-up and analyses of withdrawals were not applicable.
Of the 4 cross-sectional studies[22, 36, 41, 50] included for the methodological quality
assessment; two studies[22, 50] scored seven (7) and the other two[36, 41] scored six (6) out of
seven (7) JBI critical appraisal criteria. The patient sample was representative, and confound-
ing factors were controlled. Comparisons, description and appropriate statistical analysis were
made in all included studies. However, since these studies were cross sectional, appraisal based
on adequate follow-up and analyses of withdrawal were not applicable.
Summary of risk of bias of the included studies was assessed using Agency for Healthcare
Research and Quality (AHRQ) criteria and is presented in S3 Table. The extent of risk bias was
almost similar, and the studies had ‘low risk’ bias in the majority of areas. Due to inapplicabil-
ity of design nature of the studies, they had ‘unclear risk’ judgment in a few criteria assessing
the bias.
Measurement of LP
Measures of LP were based on delayed (late) HIV diagnosis, delayed (late) HIV testing, or
delayed entry to care after HIV positive test result and is presented in Table 1. Six (6) studies
[14, 22, 23, 40, 41, 49] defined LP as having CD4 count below 200 or WHO stage 3 or 4 at the
time of enrollment. Three studies[19, 48, 50] measured LP as having CD4 count below 350 or
WHO stage 3 or 4 at the time of enrollment. One study[36] measured LP when patients had
CDC HIV disease-stage classification B or C at diagnosis.
The association of stigma and LP
Five (50%) studies[23, 40, 41, 48, 49] found a significant association between stigma and LP.
Abaynew and colleagues[23] depicted that HIV infected patients who perceived high stigma
were about 3 times (AOR = 3.1, 95%CI: 1.1–8.8) higher to LP than those who perceived low
stigma. In their study, Aniley and colleagues[48] revealed that those who perceived high stigma
were about 2 times (AOR = 1.7, 95%CI: 1–2.9) at high risk of LP when compared to those who
perceived low stigma. Beyene and colleagues[49] presented that HIV positive adults with high
and medium stigma score had the highest rates of LP than those with low stigma score (AOR
(high vs low internalized stigma score) = 16.6, 95% CI: 8.3–33.4; (medium vs low internalized
Table 1. (Continued)
Author Year Country Design Population Setting n Outcome Outcome Measurement Key findings
Nyika et al.
[40]
2016 Zimbabwe Case
control
HIV + adults Clinic 268 LP Late presenters were HIV
positive individuals who had
WHO clinical stage 3 or 4
irrespective of CD4
lymphocyte count or a CD4
lymphocyte count of less than
200/uL irrespective of clinical
staging at the time of first
presentation to the ART clinics
of the hospitals.
Stigma was statistically
associated with LP (AOR = 2.9,
95%CI: 1.5, 5.8).
Onyango
et al.[22]
2009 Kenya Cross-
sectional
HIV + adults Public
hospital
196 LHT Patients were defined as late
testers if they were in WHO
stage 3 or 4 or had a CD4
count < 200 at the time of
enrollment.
Stigma was not a significant
predictor for LHT AOR = 1.2,
95%CI: 0.7, 2.1).
https://doi.org/10.1371/journal.pone.0173928.t001
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stigma score) = 4.9, 95%CI: 3.1–7.8). Similarly, Nyika and colleagues[40] mentioned that
patients who had stigma were 3 times (AOR = 2.9, 95%CI: 1.5, 5.8) higher to LP than those
who did not have stigma. In contrary to the above findings, Carrizosa and colleagues[41]
showed that HIV positive adults who feared stigma had low LP rate (AOR = 0.7, 95% CI: 0.5–
0.9) than those who did not fear stigma.
Meta-analysis of the association of stigma and LP
This meta-analysis identified the association of stigma and LP by using proportions, not spe-
cific estimates, assessed in primary studies[14, 22, 23, 36, 40, 41, 48–51] to estimate the pooled
effect size. Random effects meta-analysis model was used for studies having moderate hetero-
geneity level when combined[43, 45, 46]. Two studies[22, 50] were excluded from the meta-
analysis calculation to prevent the introduction of significant heterogeneity. The majority
(67%) of study population in the Kenyan study[22] have completed post-primary school com-
pared to the study population of the other studies included in the meta-analysis, and this popu-
lation characteristics difference in educational status could be the reason for heterogeneity.
Furthermore, the study population in the Brazilian study[50] were men who have sex men—a
population with different characteristics with the heterosexual population of the other studies
included in the current meta-analysis—could be the main source of heterogeneity. The Mantel
Haenszel statistical method was used to calculate effect sizes. Forest plots for the meta-analyses
of stigma, a graph that presents the point estimate of pooled effect size with its 95%CI for each
included study, is shown in Fig 2. The meta-analytic association suggests that the odds of LP
was two times higher in patients who perceived high stigma compared to those patients who
perceived low stigma (Fig 2, pooled odds ratio = 2.4; 95%CI = 1.6, 3.6, I2 = 79). However, since
there was a moderate heterogeneity (I2 test = 79%, p<0.0001), this conclusion should be inter-
preted cautiously. A meta-analysis of the adjusted ORs gave similar results but heterogeneity
between studies was very high (>90%). The funnel plot output confirmed the absence of publi-
cation bias. In addition, sensitivity test was performed, and showed no differences except
when the excluded studies due to heterogeneity were included.
Discussion
In more than thirty years of the HIV epidemic we still have major HIV related discrimination
and stigma, one of the situations that undermine the HIV response globally[52]. Previous stud-
ies evaluating HIV related stigma and HIV care have identified stigma as a key impediment
for timely initiation of ART treatment[14, 22, 23, 27, 36, 40, 41, 48–51]. Nevertheless, few stud-
ies have been published as demonstrated by the low number of articles (10 studies) over a
14-years period included in this meta-analysis. As far as is known, there are no previous sys-
tematic reviews or meta-analyses that have examined the association between stigma and LP.
This systematic review and meta-analysis identified studies conducted in six countries of
which eight (8) out of the 10 included studies were from Africa.
Fig 2. Forest plot of meta-analytic association between stigma and late presentation for HIV care. It
shows that the risk of late presentation for HIV care is higher for patients who perceived high HIV related
stigma than their comparator.
https://doi.org/10.1371/journal.pone.0173928.g002
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The current study identified that stigma was a risk factor for LP. This was corroborated by a
six-country comparison study in Europe reporting that stigma was a risk factor for timely HIV
care engagement[53]. Even if the timing was not evaluated, a systematic review from India[54]
depicted that HIV related stigma was a key reason for low HIV testing uptake and a common
barrier to accessing ART services. In addition, other systematic reviews reported that stigma
was a big challenge for HIV testing[55–58], and HIV care linkage[56, 59]. This indicates that
stigma influences in every series of HIV care continuum.
In the first continuum step, HIV infection diagnosis, people might keep out from seeking
HIV testing due to fears surrounding the test and the possibility of receiving HIV-positive
diagnosis[58]. Failing to obtaining a timely diagnosis could results in increased likelihood of
continuous transmission[24, 60], worsened response to ART [23, 25, 26], and increased mor-
bidity and mortality [4, 23, 25, 26, 61]. Thus, health professionals should be informed that
stigma delays timely presentation for HIV care. Furthermore, the community should be made
aware of the consequences of stigma on HIV testing, and HIV testing rates should be enhanced
using effective structural approaches including rapid and provider-initiated[62], mobile[63]
and home based[64] testing. The Theory of Planed Behavior [65, 66] and Health Belief Model
[67, 68] have emphasized that the likely of adapting a health behavior is reliant on the extent of
intention to execute the behavior, which, in turn, is persuaded by other psychological aspects
such as behavioral attitudes. For instance, with regard to HIV testing, behavioral attitudes
might involve belief concerning the benefits of testing stating that HIV testing aids people to
seek treatment if they are HIV positive
In the second continuum step, linkage to care, stigma contributes to late engagement to
HIV care either due to late HIV testing[58] or late linkage to HIV care after early diagnosis
[53]. This could be attributed to fear of disclosing their status to other patients or health care
providers. Hence, it is mandatory to reduce stigma and discrimination; facilitate access to HIV
related legal services (e.g. violations of confidentiality, discrimination in employment, educa-
tion, housing or social services); monitor and reform HIV related laws, regulations and poli-
cies; sensitize law-makers and law enforcement agents; and train health care providers on
human rights and HIV related medical ethics[52].
The effect of stigma on the first and second steps of HIV care continuum could further
challenge the next series of the continuum care. Thus, in the third and fourth continuum
steps, retention in care with good adherence, stigma has also been identified to have a signifi-
cant influence. Evidence from qualitative studies suggested an existence of an association
between stigma and retention in HIV care[69–71]. Other studies have reported an association
between stigma and poor adherence to medication [72–74]. Such correlation of stigma and
HIV care retention reinforce the complex nature of HIV stigma and the multi-layered strate-
gies that enforce to reduce HIV stigma to improve the outcomes of each series of HIV care
continuum[71].
The current evidence on the association between stigma and LP has important gaps. Mea-
sures for LP were disparate to be analyzed systematically. This limitation is suggestive of weak-
nesses in definition of LP, which continues to lack a ‘gold standard’ measurement method
contextually. The majority of the studies were conducted in Africa and all of the studies were
conducted in developing countries. It is highly likely that the correlation of stigma and LP in
LMICs and HICs could be dissimilar and as such urgent attention would be warranted to
assess the problem.
This meta-analysis doesn’t show the degree of association in each series of time to HIV care
presentation: late HIV testing/diagnosis, late enrolment in pre-ART care though diagnosed
early, late ART care enrolment though diagnosed early and successfully enrolled in pre-ART
care. Only Onyango and colleagues[22] reported the association of stigma with late HIV
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testing and late HIV care after testing. This shows a significant oversight for the need of future
research on the influence of stigma to HIV testing and engagement to care even after early
HIV testing.
The current study has several limitations and should be interpreted cautiously. All of the
included articles in this review were not prospective. This implies that meta-analytic result
may not show causal relation. The search strategy was limited to English language and this
could lead to reporting bias[75]. Only quantitative studies were included due to limited avail-
ability of qualitative studies during the review period of this meta-analysis. Geographic skew-
ness and inclusion of few studies could influence the generalizability of the findings.
Nevertheless, stigma is still a big problem in developed countries[76, 77] and some of the
aforementioned interventions can contextually be reshaped. One study[41] did not explicitly
report absolute numbers of patients who delayed for HIV care by their status of stigma. An
effort to contact the corresponding author of the study was fruitless and hence, we have been
unable to include in the meta-analysis.
We focused the systematic review on general HIV positive adults, but such analysis should
be followed by another work to assess the same among children, and other key populations
such as MSM, lesbians, FSW, and long distance truck drivers. In addition, future reviews should
consider sub group analysis of stigma by place of residence (urban, rural), sex (male, female),
population (general, MSM/lesbian, FSW) and type of stigma (experienced stigma in health care
setting, stigma in household or community, internal stigma and perceived discrimination). The
nature of stigma requires qualitative explorations; hence systematic review and meta-analysis of
qualitative studies should also be performed. Finally, the presence of moderate heterogeneity (I2
= 79) could be attributed to differences in study design, study area, sample sizes of individual
studies (chance), and measurements of exposure and outcome (measurement errors)[78].
Conclusions
We found that high perceptions of stigma significantly contributed for LP. Health profession-
als should play a key role in behavioural change of patients (e.g. structural and or social mar-
keting interventions aiming to reduce HIV related stigma) on how to break the feeling of
stigma and the benefit of early HIV diagnosis or entry to HIV care. Frequent HIV testing cam-
paign, even to the extent of home-to-home visit, should be conducted to address individuals
who did not get tested due to fear of positive result or stigma. Linkage system and frequent
positive case tracing after people are tested should be strengthened.
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